Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs MICARDIS HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Treatment of hypertension, alone or in combination with other antihypertensive agents
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
Intravenous: 100% (only route of administration).
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Safety and efficacy not established in pediatric patients (<18 years).
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
None.
None
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs MICARDIS HCT, answered by our medical review team.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and MICARDIS HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and MICARDIS HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.